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Tau is an axonal microtubule-associated protein involved
in microtubule assembly and stabilization. Mutations in
Tau cause frontotemporal dementia and parkinsonism
linked to chromosome 17 (FTDP-17), and tau aggregates
are present in Alzheimer’s disease and other tauopathies.
The mechanisms leading from tau dysfunction to neuro-
degeneration are still debated. The dynein–activator com-
plex dynactin has an essential role in axonal transport and
mutations in its gene are associated with lower motor
neuron disease. We show here for the ﬁrst time that the
N-terminal projection domain of tau binds to the C-termi-
nus of the p150 subunit of the dynactin complex. Tau and
dynactin show extensive colocalization, and the attach-
ment of the dynactin complex to microtubules is enhanced
by tau. Mutations of a conserved arginine residue in the N-
terminus of tau, found in patients with FTDP-17, affect its
binding to dynactin, which is abnormally distributed in
the retinal ganglion cell axons of transgenic mice expres-
sing human tau with a mutation in the microtubule-bind-
ing domain. These ﬁndings, which suggest a direct
involvement of tau in axonal transport, have implications
for understanding the pathogenesis of tauopathies.
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Introduction
The neuronal microtubule (MT)-associated protein tau plays
an important role in the organization of axonal MTs (Lee
et al, 2001). Tau is also the major component of the neuroﬁ-
brillary pathology that deﬁnes Alzheimer’s disease and other
related neurodegenerative disorders. Furthermore, mutations
in the tau gene cause a familial form of dementia (fronto-
temporal dementia and parkinsonism linked to chromosome
17 (FTDP-17)), indicating that dysfunction of tau protein is
sufﬁcient to cause neurodegeneration (Yancopoulou and
Spillantini, 2003). In adult human brain, there are six tau
isoforms produced from a single gene by alternative mRNA
splicing (Goedert et al, 1989). They differ by the presence of
three or four MT-binding repeats in the C-terminal region
(with the extra repeat encoded by exon 10) and the presence
or absence of 29 or 58 amino-acid inserts (encoded by exons
2 and 3) in the N-terminal region. Tau consists of two major
parts, a C-terminal MT-binding region and an N-terminal
projection domain (Hirokawa et al, 1988; Kar et al, 2003a).
Unlike the MT-binding region, relatively little is known about
the function of the projection domain. It has previously been
implicated in determining the spacing between MTs (Chen
et al, 1992) and in mediating the interactions between tau
and the plasma membrane (Brandt et al, 1995). Interestingly,
mutations of a conserved arginine (R5) in exon 1 have been
implicated in cases of human dementia (Hayashi et al, 2002)
and progressive supranuclear palsy (Poorkaj et al, 2002).
The dynactin complex is found in many cell types, includ-
ing neurons, and plays an important role in mediating the
binding of the MT motor complex dynein to its membranous
cargoes (Holzbaur et al, 1991; Schroer, 2004). Dynactin
consists of a short ﬁlament of an actin-like protein, ARP1,
and around 10 other polypeptides, including a dimer of the
heavy chain, known as p150. This extended protein binds
alongside the ARP1 ﬁlament and forms a sideways coiled-coil
extension, tipped with a pair of globular N-terminal domains.
The latter are MT-binding CAP-Gly domains (Schroer, 2004).
The ARP1 ﬁlament is thought to be able to interact with the
layers of actin ﬁlaments that lie in contact with cell mem-
branes. Dynactin plays an essential role in axonal transport
(Holzbaur et al, 1991; Waterman-Storer et al, 1997; Schroer,
2004) and its mutations have been associated with motor
neuron disease (Puls et al, 2003, 2005; Mu ¨nch et al, 2005).
Here we show that the projection domain of tau interacts
directly with the C-terminus of p150 the major component of
the dynein–activator complex dynactin. This binding is af-
fected by the mutation of a conserved arginine residue in
position 5 in exon 1 of the tau gene, which causes FTDP-17
(Hayashi et al, 2002; Poorkaj et al, 2002). We also show that
tau facilitates the binding of p150 to MTs and that tau and
p150 are colocalized and abnormally distributed in retinal
ganglion cell (RGC) axons from a transgenic mouse line
expressing human tau with the P301S mutation in the MT-
binding domain (Allen et al, 2002).
Results
Bacterial two-hybrid screen
A bacterial two-hybrid screen of a human brain cDNA library
using exons 1–4 of Tau (Figure 1) as the bait yielded ﬁve
positives, one of which corresponded to the 113 C-terminal
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4546amino acids of p150 (residues 1166–1278). The latter was
then used as the bait against full-length tau or against
constructs consisting of Tau exons 1 and 4; exons 1, 2 and
4; and exons 1–4. Full-length tau1–13 (the 441-amino-acid
isoform of human brain tau (clone htau40)) and all three N-
terminal fragments interacted with the C-terminal part of
p150. These results indicated that the interaction occurs
between the C-terminus of dynactin and the sequence en-
coded by exons 1 and 4 at the N-terminus of tau, whereas
exons 2 and 3 are not necessary for this binding.
In vitro binding assays of tau and dynactin
To further characterize the association between tau and p150,
we performed in vitro binding assays of a range of recombi-
nant protein fragments. GST-tagged tau fragments and His-
tagged p150 fragments were bound to magnetic beads coated
with anti-tag antibodies and interacting proteins were visua-
lized by SDS–PAGE and immunoblotting (Figure 2). Besides
wild-type tau, R5H and R5L tau mutants as well as partial
sequences consisting of exons 1–3, 2–4 and 5–13 (tau1–3,
tau2–4 and tau5–13, respectively) were used (Figure 1). Full-
length p150 (which tended to aggregate and degrade into
shorter fragments, even after isolation), an N-terminal frag-
ment (residues 1–210, p150N), a middle fragment (residues
550–940, p150M) and a near C-terminal fragment (residues
900–1200, p150C) were tested (Figure 1). Several alternative
C-terminal fragments containing the sequence after residue
1200 were expressed as insoluble protein and could not be
used.
Full-length p150 as well as the p150C fragment bound to
GST-tagged tau1–3 or tau2–4, which also interacted with a
detectable amount of native dynactin complex (Figure 2A–C
and E). Fragments p150N and p150M, however, did not bind
to tau fragments containing the projection domain (Figure
2A–C). These ﬁndings indicate that the tau-binding site lies
within the C-terminal 338 amino acids of p150. However,
neither p150C nor full-length p150 bound to the tau5–13 GST
fusion protein (Figure 2A, D and E). When full-length His-
tagged p150 or p150C was used as bait, full-length tau1–13
and its N-terminal fragments did bind (Figure 2F–H),
whereas tau5–13 did not (Figure 2F). In contrast, when
p150N or p150M was used as bait, no tau proteins bound
(Figure 2G and H). These ﬁndings, summarized in Figure 2A,
conﬁrm that the p150-binding site lies on an extended part of
the projection domain of tau, encoded by exons 1–4.
Effect of tau N-terminal mutations R5L and R5H
Since mutations R5L and R5H are known to cause tau
dysfunction and aggregation in vivo, we expressed full-length
tau proteins containing these mutations and investigated
their interaction with p150C in pull-down assays. As shown
in Figure 3, p150-associated magnetic beads are able to pull
down a clearly detectable amount of wild-type tau. However,
only a trace amount of tauR5L and no tauR5H bound to the
beads. Thus, when tau’s exon 1 sequence is present, residue
R5 is very important for the binding to dynactin.
Binding of dynactin complex to MTs with and
without tau
Tau and p150 have distinct MT-binding domains (Waterman-
Storer et al, 1995; Lee et al, 2001). In order to clarify whether
their interaction modulates their individual MT-binding prop-
erties, and to gain insight into the physiological role of this
interaction, we investigated the binding of dynactin to MTs in
vitro in the presence and absence of tau. MTs were assembled
from puriﬁed pig brain tubulin with and without recombinant
full-length tau, incubated either with whole dynactin com-
plex puriﬁed from pig brain or with recombinant p150, and
then pelleted. Dynactin fragments p150M and p150C did not
bind to MTs under any condition. Tau and p150N were found
to compete for binding sites on the MTsurface. The presence
of tau did not signiﬁcantly change the amount of p150N in
the pellet, but less tau appeared in the pellet when p150N was
present than when it was absent (data not shown). It is not
surprising that p150N is able to displace some tau, since
excess tau molecules bind to the outer surface of an MT by
means of multiple weak binding sites (Kar et al, 2003b;
Makrides et al, 2004). Whole native dynactin complex pur-
iﬁed from pig brain (see Materials and methods) also bound
to MTs and pelleted with them, irrespective of tau’s presence
or absence. However, the amount of dynactin complex in the
pellet increased when tau was included (Figure 4A and B).
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Figure 1 Schematic representation of dynactin p150 functional
domains and dynactin p150 and tau DNA fragments used for in
vitro experiments. (A) p150 functional domains and associated
coiled-coil domains (plot); dynein- and ARP1-binding domains
overlap with two main coiled-coil domains in the protein structure;
a small coiled-coil domain is present near the C-terminus, around aa
1200, overlapping with the tau-interacting region identiﬁed in this
work. (B) His-tagged N-terminal (p150N; aa 1–210), central
(p150M; aa 550–940), C-terminal (p150C; aa 900–1200) and full-
length p150 used for in vitro binding experiments. (C) The 441-
amino-acid isoform of human brain tau (htau40, exons 1–13)
contains a C-terminal MT-binding domain with 4 repeats (black
boxes) one of which (encoded by exon 10, indicated in orange) is
missing from tau isoforms with three repeats. The N-terminus
contains alternatively spliced exon 2 (magenta) and exon 3 (yel-
low). Full-length tau1–13 and fragments N0, N1 and N2 were used
in the bacterial two-hybrid screening. Tau1–13 and GST-tagged
tau1–3, tau2–4 and tau5–13 constructs were used for in vitro
binding experiments.
Tau interaction with dynactin p150
E Magnani et al
&2007 European Molecular Biology Organization The EMBO Journal VOL 26 | NO 21 | 2007 4547The association between MTs and the native dynactin
complex was investigated further by negative stain electron
microscopy. When pig brain dynactin complex was added to
the sample, we saw structures resembling the dynactin com-
plex described by Schafer et al (1994), which were not visible
when only tau was present. Complex-like structures attached
to the MTappeared similar in the absence of tau or presence
of N-terminally mutated tau, but were always rather sparse.
In a typical experiment, we counted an average of 2274
(n¼3) projections per micrometer of MT when full-length
wild-type tau was present, compared with an average of 872
(n¼3) when either no tau or R5L-tau was present. In order to
identify these MT-interacting structures, we carried out im-
munolabelling with an anti-p150 primary antibody followed
by gold-conjugated secondary label and found that gold
particles decorated the entire lengths of MTs assembled in
the presence of normal tau (Figure 5A). When dynactin
complex was added to MTs assembled with N-terminally
mutated tau, however, the amount of label along the MT
was similar to background level (Figure 5B). The difference in
decoration seen by EM is greater than that measured in the
pelleting assay (Figure 4), possibly because any aggregated
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Figure 2 Binding of tau, dynactin p150 and their fragments. (A) Table summarizing the results of in vitro binding of tau.GSTand p150.His or
native dynactin complex using anti-tag-coated magnetic beads. ( ), no binding; (þ), binding observed. (n) native dynactin and (r)
recombinant dynactin p150 were used in these experiments. (B–G) SDS–PAGE analysis of protein complexes interacting with anti-GST and
anti-His antibodies on beads. Gels show proteins eluted from the beads and stained with Page-Blue 83. All the results were conﬁrmed by
immunoblotting (not shown). (B–D) GST-tagged recombinant tau fragments (B, tau1–3.GST; C, tau 2–4.GST; D, tau 5–13.GST) were used as
bait for interaction with p150 and its fragments. t, only tau.GST fragments mixed with beads; N: tau.GST fragments with p150N.His; M:
tau.GST fragments with p150M.His; C: tau.GST fragments with p150C.His. Only p150C.His binds to tau1–3 and 2–4 GST-tagged fragments. (E)
Tau.GST fragments were used as bait for the native dynactin complex. d, native dynactin complex alone (bands corresponding to p150, p50 and
ARP1 are visible); 1–3: tau1–3.GST with native dynactin; 2–4: tau 2–4.GST with native dynactin; 5–13: tau 5–13.GST with native dynactin.
Tau1–3.GST and tau 2–4.GST bind to native dynactin, but the tau 5–13.GST fragment does not. (F) p150C.His was used as bait and its
interaction with tau.GST fragments and untagged full-length tau1–13 was tested. 1–3: p150C.His with tau1–3.GST; 2–4: p150C.His with tau2–
4.GST; 5–13: p150C.His with tau5–13.GST; 1–13: p150C.His with full-length tau1–13.GST. tau1–3.GST, tau2–4.GST and tau1–13.GST bind to
p150C.His but not the tau5–13.GST fragment. (G) SDS–PAGE of protein complexes interacting with p150.His constructs bound to anti-His
antibodies on beads. Interaction of full-length tau1–13 with p150N.His (lane 1), p150M.His (lane 2) and recombinant full-length p150.His and
fragments (lane 3). Since full-length His-tagged p150 had a strong tendency to aggregate and degrades during puriﬁcation, only a small amount
was available for binding to beads. Therefore, the untagged full-length tau protein that bound to p150.His on the beads was detected by
immunoblotting with the anti-tau antibody BR133 as shown in (H). (H) Immunoblot of pellets in lanes 1–3 of panel G using BR133 of proteins
interacting with p150N.His, p150M.His and p150.His bound to anti-His antibodies on beads. N: untagged full-length tau1–13 with p150N.His;
M: untagged full-length tau1–13 with p150M.His; p150: untagged full-length tau1–13 with full-length p150.His. Tau1–13 binds to full-length
recombinant dynactin (p150.His) but not to its fragments p150M.His and p150N.His.
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the dynactin appeared to aggregate less when wild-type tau
was present. When tau was not present, dynactin appeared to
aggregate particularly at the ends of MTs.
In higher magniﬁcation images, the actin-like ﬁlaments
that form part of the complex can be seen extending sideways
from the ends of ﬁne projections from the MT outer surface
(Figure 5C–E). When tau was present, we often saw such
structures in series, at intervals of B30 or 40nm (Figure 5A
and C). There is a potential binding site for a dynactin
projection on every tubulin heterodimer in the MT lattice,
8nm apart along each protoﬁlament, but either the actin-like
ﬁlaments prevent the complexes from binding so closely and/
or the intervals may be determined by the space between tau
projections.
Localization and immunoprecipitation of tau and
dynactin in differentiated SH-SY5Y cells
To look for an interaction between p150 and tau in living
cells, we used untransfected, differentiated human neuro-
Figure 3 Pull-down assays of mutant tau and the C-terminal frag-
ment of p150. SDS–PAGE of proteins bound to magnetic beads
coated with anti-His antibodies. Dynactin fragment p150C.His was
incubated with wild-type tau1–13 (lane 1), tauR5L (lane 2) and
tauR5H (lane 3). Wild-type tau1–13 binds to p150C, but mutant
tau1–13 R5L and R5H show a much reduced and absent binding,
respectively.
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Figure 4 In vitro interaction of native dynactin complex with MTs
and the effect of tau. (A) SDS–PAGE of proteins in the pellet (P) and
supernatant (S), when puriﬁed native pig brain dynactin was
incubated with MT assembled from puriﬁed pig brain tubulin,
with or without recombinant tau1–13. (B) Integrated densities (in
arbitrary units) obtained by densitometry of p150 bands in the
pellet lanes of panel A.
Figure 5 Electron microscopy and immunoelectron microscopy of
native dynactin complex on MTs. (A, B) Immuno-EM of native
dynactin bound to MT and labeled with anti-p150 and protein A
conjugated with 20nm gold and then negatively stained. Arrows
point to gold particles on MT. MT in panel A were assembled with
4mM full-length wild-type tau, those in panel B with 4mM R5L
mutant tau. Scale bar, 100nm. (C–E) Negative staining images of
MT assembled with 4mM wild-type tau and decorated with native
dynactin. Arrows indicate ﬁne dynactin-like stalks, tethering short
ARP1 ﬁlaments to the MT. Scale bar, 50nm. (F) A model of the way
that p150 in the dynactin complex interacts with an MT and the
projection domain of tau, as indicated by data in Figures 2–5.
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experimental conditions (10mM retinoic acid (RA) for 2
weeks, 50ng/ml brain-derived neurotrophic factor (BDNF)
for 4 days), SH-SY5Y cells express only the shortest three-
and four-repeat tau isoforms without amino terminal inserts
(Figure 6B). By immunoprecipitation with anti-tau antibody
BR133, a fraction of p150 co-sedimented with these tau
isoforms (Figure 6A and B), consistent with the ﬁnding
from the bacterial two-hybrid experiments that exons 2 and
3 of tau are not required for p150 binding. Not all dynactin
p150 is immunoprecipitated by anti-tau antibodies, as ex-
pected by the higher abundance of dynactin p150 in SH-SY5Y
cell extracts. Immunoprecipitation using anti-p150 antibodies
was also performed, but tau runs at the same level as the
antibody chains and the nonspeciﬁc background did not
produce results clear enough to be shown.
Immunocytochemistry shows that tau and dynactin p150
co-localize in the cellular compartments of differentiated
SH-SY5Y cells (Figure 6C–E).
Localization of tau and p150 dynactin in RGC axons of
transgenic mice expressing mutant P301S human tau
These ﬁndings raised the question of whether a deﬁcit in tau
would also affect the dynactin complex. To this aim, we used
mice transgenic for human tau with the FTDP-17 mutation
P301S (Allen et al, 2002) and studied the distribution of tau
and p150 in the axons of RGCs from organotypic cultures
(Figure 7). We examined only axons with intact, continuous
staining for neuroﬁlament H, to avoid those with a general-
ized defect in axonal transport. RGCs prepared from these
transgenic mice express human transgenic tau (Gasparini
et al, 2006). Tau staining was strong and with some accumu-
lations in RGC axons from transgenic mice (Figure 7A). This
differed from what was observed in control mice, where tau
staining was weaker and more homogenously distributed
(Figure 7B). In control RGCs, staining for p150 was concen-
trated in the distal axons and growth cones, as previously
described (Abe et al, 1997), while it was weak in the proximal
and intermediate portions of the axons. This stood in marked
contrast to the irregular globular p150-immunoreactive struc-
tures, which colocalized with tau accumulation in axons from
transgenic mice (Figure 7A). These ﬁndings are in agreement
with an association between tau and p150, and suggest that
tau dysfunction can result in the mislocalization of dynactin
in axons even when neuroﬁlament staining appears normal.
Discussion
An increasing number of studies supports the hypothesis that
defects in axonal transport are responsible for neurodegen-
erative diseases (LaMonte et al, 2002; Holzbaur, 2004). Here
we demonstrate a direct interaction between tau protein and
dynactin p150, two MT-binding proteins, missense mutations
in either of which can cause neurodegeneration (Puls et al,
2003, 2005; Yancopoulou and Spillantini, 2003; Mu ¨nch et al,
2005).
Axonal MTs are organized with their fast-growing (plus)
ends pointing towards the axonal tip. MTs are assembled in
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Figure 6 Localization and immunoprecipitation of tau and dynactin in differentiated SH-SY5Y cells. (A) Endogenous p150 co-immunopre-
cipitates with tau in differentiated SH-SY5Y cells. Immunoprecipitation was performed with anti-tau antibody BR133 and immunoblots with
p150 antibody. p150 dynactin is present in the pellet containing immunoprecipitated proteins (lane 1). Normal rabbit IgG instead of BR133
(lane 2), only beads (lane 3) and whole-cell extract (lane 4) were used as controls. (B) SH-SY5Y cells express only the shortest three- and four-
repeat tau isoforms as detected by immunoblotting of cell extracts with anti-tau antibody BR133. Lane 1, six recombinant human tau isoforms;
lane 2, SH-SY5Yextracts. The two shortest tau isoforms with three and four repeats and no N-terminal inserts are present. (C–E) Tau and p150
colocalized in the cellular compartments of differentiated SH-SY5Y cells. Immunoﬂuorescence labelling of tau (C) obtained with anti-tau
antibody BR133, p150 (D) stained using anti-p150 antibody and overlay (E). Scale bar: 40mm for panels C, D, E.
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2005). Tau is also found initially in the cell body, but after the
development of one of the neurites into an axon, becomes
concentrated in the distal axon. Kempf et al (1996) found that
tau’s localization to the distal axon requires intact MTs and
microﬁlaments and proposed a model in which MT-bound
tau is linked to the plasma membrane by a component that
requires actin ﬁlaments for its subcellular localization. Our
results suggest that the dynactin complex could be that
component and support the idea that tau-stabilized MTs
could be transported in the anterograde direction along the
axon by dynein/dynactin motors linked to the axonal mem-
brane. F-actin is another component of the anterograde
axonal transport machinery and may be carried along with
MTs through dynactin-mediated links as recently suggested
(Fulga et al, 2007). Dynein/dynactin complexes also play a
vital role in retrograde transport of vesicular cargoes. In this
case, the presence of tau could help to assist dynein/dynactin
interactions with MT tracks.
Our model of the molecular interaction between tau and
p150 is shown in Figure 8. Both proteins bind independently
to MTs. Tau can bind via multiple sites to several tubulin
heterodimers, but may bind weakly to a small number of sites
when excess amounts of tau are present. The binding site for
p150 appears to overlap with some of the weaker binding
sites for tau. However, when tau and p150 are present at
physiological levels, they would be able to bind alongside
each other, but to separate sites. According to our data, tau
appears to stabilize the binding of the dynactin complex. The
sequences of tau encoded by exons 1 and 4, which lie at the
tip of the N-terminal projection domain, interact with the C-
terminal region of p150. Neither exon 1 nor 4 appears to be
essential for this interaction, with just one of them being
sufﬁcient; however, when exon 1 is present, an arginine at
position 5 is required for p150 binding. A detailed structural
study is needed to fully explain these complexities.
The C-terminal region of p150 to which the tau projection
domain binds, occupies the portion of the dynactin complex
that also projects away from MTs. Previously, the MT-binding
proteins EB1 and CLIP170 have been shown to regulate the
afﬁnity of dynactin for MTs via the tubulin-binding N-term-
inal domain of p150 (Berrueta et al, 1999; Goodson et al,
2003; Lansbergen et al, 2004). Our ﬁndings suggest that tau
facilitates the association of the dynactin complex with MT
tracks by binding to the C-terminus of p150. Although other
components of the dynactin complex bind to p150 in this
extensive C-terminal region, a recent structural study has
shown the presence of additional binding sites (Imai et al,
2006).
Our ﬁndings also indicate that the dysfunction of tau
caused by FTDP-17 mutations, such as P301S, may affect
the normal function of the dynactin complex. Further studies
are needed to determine how a dysfunction in tau affects
dynactin-related axonal transport. Our attempt to perform
this study in RGC axons derived from P301S human tau
transgenic mice (data not shown) has been hampered by a
likely compensatory action of endogenous mouse tau on the
effect of the human P301S mutant tau. Previous studies have
shown that mouse tau is not involved in the aggregation of
P301S tau (Allen et al, 2002). Missense Tau mutations reduce
the ability of tau to interact with MTs, which may in turn
result in the assembly of tau into abnormal ﬁlaments and
impaired axonal transport (Hasegawa et al, 1998; Zhang et al,
2004). In RGC axons from mice transgenic for human P301S
tau, p150 was redistributed and colocalized with abnormal
p150
tau
NF NF
tau
p150
AB
Figure 7 Colocalization of tau and p150 in RGC axons from P301S human tau transgenic mice. Retinal organotypic cultures from P301S human
tau transgenic mice (A) and age-matched control mice (B) were cultured for 7 days and stained for p150 (green), tau (red) and neuroﬁlament H
(NF, blue). Arrows indicate the sites of accumulation of p150 and tau. Scale bars, 5mm. Axons shown here are representative of 150 ﬁelds
observed in transgenic and control mice in three independent experiments.
Figure 8 A model of the role of tau in stabilizing the interaction
between axonal MTs and the dynactin/dynein complex. In this
model the repeat region of tau binds to the inner surface of the
MT lattice, part of tau (black line) binds to the outside surface,
while the N-terminal domain projects away from the MT surface
(Kar et al, 2003a,b). p150 binds to MT via its globular N-terminal
domains. The interaction with tau might stabilize this association.
Our data indicate that the projection domain of tau interacts with
the C-terminal part of p150, which also binds to a short actin-like
ﬁlament (Arp1 plus several other components; Imai et al, 2006).
The latter part of the dynactin complex is able to contact vesicular
cargoes as well as the cell membrane. Dynactin stabilizes the
interaction of dynein with MTand mediates its binding to cargo.
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tau could lead to a redistribution of the dynactin complex and
its reduced association with MTs, which could contribute to
the clinical and neuropathological phenotype of FTDP-17 and
other tauopathies.
Materials and methods
Antibodies
The following antibodies were used: polyclonal BR133 recognizing
the N-terminus of tau and anti-p150(Glued) antibodies (BD
Biosciences, San Jose, CA, USA) (Chemicon, Temecula, CA), anti-
p150 antibody (DCTN1) (Abcam, Cambridge, UK) and SMI-31
monoclonal antibody (Sternberger Monoclonals Inc., Berkeley, CA)
against phosphorylated neuroﬁlament proteins.
Cloning, expression and puriﬁcation of p150 and tau proteins
The coding sequences of the N-terminal part of tau isoforms were
ampliﬁed from htau44, htau46 and htau40 cDNAs using the primers
N-Tauf (50-CTAGAATTCCATGGCTGAGCCCC-30) and N-Taur (50-CT
ACTCGAGAGCTTGGGTCACGT-30), and ligated into EcoRI/XhoI-cut
pBT bait plasmid (Stratagene, La Jolla, CA). Full-length tau was
ampliﬁed from htau40 cDNA using N-Tauf and Taur (50-GACTCTCG
AGTCACAAACCCTG-30) primers and subcloned into pBT. p150 was
cloned from human brain cDNA (Clontech, Mountain View, CA)
using the primer pair p150f/p150r (50-GACTCTCGAGTATGGCACAG
AGCAAG-30/50-GACTGGTACCTTAGGAGATGAGGCG-30) in a PCR
reaction with Pfu Turbo polymerase (Stratagene, La Jolla, CA).
The resulting PCR product was puriﬁed and ligated into XhoI/KpnI-
cut pRSETB (Promega, Southampton, UK) for the expression of
N-terminal His-tagged protein.
The coding sequences of tau fragments tau1–3, tau2–4 and tau5–13
(Figure 1) were ampliﬁed from htau40 cDNA using the primer pairs
Tau1-3f/Tau1-3r (50-CTAGAATTCATGGCTGAGCCCCG-30/50-CTACTC
GAGTCATGTGGTTCCTTC-30), Tau2-4f/Tau2-4r (50-CTAGAATTCGAA
TCTCCCCTGC-30/50-CTACTCGAGTCATTGGGTCAC-30) and Tau5-
13f/Tau5-13r (50-CTAGAATTCGCTCGCATGGCT-30/50-CTACTCGAGT
CACAAACCCTG-30), respectively, and subcloned into EcoRI/XhoI-
digested pGEX-4T-1 (GE Healthcare, Piscataway, NJ). Fragments of
human p150 were cloned into the vector pHis17 as described (Ljwe
and Amos, 1998) and the expressed His-tagged proteins p150N,
p150M, p150C and full-length p150 were puriﬁed under native
conditions by standard protocol on an Ni-NTA Superﬂow HPLC
column, as instructed by the manufacturer (Qiagen, Hilden,
Germany). Human tau fragments tau1–3, tau2–4 and tau5–13
(Figure 1) were cloned into pGEX-4T-1. GST-tagged tau fragments
were expressed and puriﬁed on a GSTafﬁnity column under native
conditions following the manufacturer’s protocol (GE Healthcare,
Piscataway, NJ). All afﬁnity-puriﬁed p150.His and tau.GST protein
fragments were run on a gel ﬁltration Sephacryl S200 column (GE
Healthcare, Piscataway, NJ) in buffer BRB80 (80mM Pipes pH 6.8,
2mM MgSO4, 1mM EGTA and 1mM DTT) and concentrated before
experiments; untagged wild-type and R5L- and R5H-mutant tau1–
13 (htau40) were expressed and puriﬁed as described (Goedert and
Jakes, 1990).
Bacterial two-hybrid screening
The screening was performed using BacterioMatchTM two-hybrid
system (Stratagene, La Jolla, CA) in combination with a human
brain plasmid cDNA library (Stratagene, La Jolla, CA). The cDNA
library, cloned into BacterioMatch pTRG target vector, was
ampliﬁed according to the manufacturer’s instructions and puriﬁed
using an EndoFree Plasmid Maxi kit (Qiagen, Hilden, Germany).
BacterioMatch two-hybrid system reporter strain competent cells
were cotransformed in pairwise combination of pTRG (containing
the cDNA library) and pBT vector (containing the N-terminus of
tau) and plated onto LB agar containing carbenicillin, tetracycline,
chloramphenicol and kanamycin for selection of putative interact-
ing clones. Colonies were ampliﬁed for further analysis and used as
DNA template in PCR reactions with pTRGf (50-CAGCCTGAAGT
GAAAGAA-30) and pTRGr (50-ATTCGTCGCCCGCCATAA-30) primers.
DNA was puriﬁed using the PCR product puriﬁcation kit (Roche
Diagnostics, Basel, Switzerland), sequenced and analyzed using
BLASTagainst the NCBI nucleotide database.
Puriﬁcation of tubulin and dynactin complex from pig brains
Tubulin was puriﬁed from pig brain as described (Hyman et al,
1991). Pig brain dynactin complex was prepared using a published
protocol (Bingham et al, 1998) and checked by immunoblotting
(Supplementary Figure). SDS–PAGE of the puriﬁed fraction showed
the numerous components of the complex, including p150, p50,
ARP1, p25 and p20. However, it did not include any of the p135
isoform lacking the N-terminal globular domain.
In vitro binding and immunoprecipitation
GST-tagged tau and His-tagged p150 fragments and full-length
recombinant or native proteins were used for in vitro binding. GST-
and His-tagged proteins were immobilized onto magnetic beads
coated with anti-GST or anti-His antibodies. Anti-His and anti-GST
antibody magnetic beads, MACS
s MicroBeads (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany), were used for studying the
interactions of tau, p150 and their fragments. Antibody-targeted
protein was ﬁrst incubated with the appropriate antibody coupled
to magnetic beads in buffer BRB80 at 301C for 20min. An aliquot of
magnetically labelled protein was then incubated with each
candidate interacting protein for a further 20min. The protein
complexes were eluted from the beads using a MACS m Column
according to the manufacturer’s instructions and analyzed by
SDS–PAGE stained by PAGE BLUE 83.
MT pelleting assay
In vitro binding of pig brain dynactin complex to MTs polymerized
from pig brain tubulin with and without recombinant tau was
assayed by co-sedimentation. Only full-length tau (wild-type or N-
terminally mutated) was used in these experiments, since tau5–13
was very poor in promoting MT assembly. Binding of proteins to
MTs was assayed by in vitro co-sedimentation analysis. Tubulin
(10mM) was assembled with or without 4mM tau for 30min at 351C
in BRB80 buffer containing 2mM of the non-hydrolysable GTP
analogue GMP.CPP. Pig brain dynactin complex (5mM) was then
incubated with MTs for a further 20min at 301C, before a 20-min
centrifugation at 96600g. Supernatants and pellets were analyzed
using 12.5% SDS–PAGE.
Electron microscopy
MTs were polymerized from pig brain tubulin in BRB80 buffer with
or without full-length tau protein, as described for the pelleting
assay, and then incubated with pig brain dynactin complex at 301C
for a further 20min. The specimens were negatively stained with
2% uranyl acetate and observed using a Philips EM208 TEM.
Images were taken at 50K magniﬁcation.
For immunoelectron microscopy, specimens were prepared as
described by Melkonian et al (2007), using an anti-p150 antibody
(DCTN1) followed by protein A conjugated to 20nm gold (BB
International, Cardiff, UK). Cytochrome c (1%) was included in
each solution as blocking agent. Grids were stained with 0.5–1%
uranyl acetate and observed using a Philips EM208S TEM with a
magniﬁcation of 28K, and micrographs were recorded using a Gatan
ES1000W CCD Camera
Cultures and immunocytochemistry of SH-SY5Y cells
The SH-SY5Y human neuroblastoma cell line was grown in
Dulbecco’s modiﬁed Eagle medium (DMEM; Invitrogen, Paisley,
UK) supplemented with penicillin (20U/ml), streptomycin (20mg/
ml) and 15% v/v heat-inactivated fetal calf serum (Invitrogen,
Paisley, UK). Cells were maintained at 371Ci n5 %C O 2 and seeded
at a density of 10
4cells/cm
2 on Petri dishes or coverslips.
Differentiation was carried out by treatment with 10mM RA (Sigma,
Poole, UK) for 2 weeks and with 50ng/ml BDNF (R&D Systems,
Minneapolis, MN) for 4 days. Differentiated SH-SY5Y cells were
ﬁxed with 4% paraformaldehyde in PBS and incubated overnight
with the primary antibody (anti-tau BR133; anti-p150, BD Bio-
sciences, San Jose, CA) diluted in 5% serum, 0.25% Triton X-100 in
PBS. Following incubation with Alexa 488- and 568-conjugated
secondary antibodies (Molecular Probes, Invitrogen, Paisley, UK),
coverslips were mounted using the ProLong anti-fade kit (Molecular
Probes, Invitrogen, Paisley, UK).
Preparation of cell extracts and immunoblotting
Differentiated SH-SY5Y cells were harvested in lysis buffer (25mM
Tris–HCl pH 7.4, 150mM NaCl, 0.1% v/v Nonidet P-40 and
complete protease inhibitor cocktail; Roche Diagnostics, Basel,
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25-gauge syringe needle. Lysates were precleared with protein A/G–
Sepharose suspension (50–100ml/ml) and incubated overnight at
41C with speciﬁc antibodies. Immunoglobulins from the same
species as the primary antibody were used as controls. Immuno-
complexes were then adsorbed with protein A–Sepharose beads.
The supernatants were collected and the beads thoroughly washed
and resuspended in 50mM Tris–HCl, pH 7.4. Supernatants and
pellets were analyzed by SDS–PAGE followed by immunoblotting.
Proteins (20–30mg) from lysates or immunoprecipitates were
separated on 9–15% SDS–PAGE gels and transferred onto Immo-
bilon-P nitrocellulose membranes (Millipore, Bedford, MA). Mem-
branes were incubated for 1h with 4% w/v Marvel milk (Premier
International Foods, Spalding, UK) in TBS and probed with primary
antibody (anti-p150, Chemicon, Temencula, CA), followed by
peroxidase-conjugated secondary antisera (1:2000). After washing,
the blots were developed using enhanced chemiluminescence
(Amersham Biosciences, Bucks, UK).
Organotypic culture of retinal ganglion neurons
Organotypic cultures of RGCs were established from C57/BL6 mice
and homozygous P301S tau transgenic mice at 5 months of age, as
described (Bates and Meyer, 1993). Brieﬂy, the mice were
anesthetized with CO2 and killed by cervical dislocation. The eyes
were removed and immediately placed in sterile Hank’s Balanced
Salt Solution (HBSS) supplemented with 5mM Hepes, 44mM
sodium bicarbonate and 16mM glucose. The retina was removed
under sterile conditions and sectioned into 400-mm squares using a
McIlwain tissue chopper. The retinal segments were then placed on
acid-cleaned glass coverslips coated with 0.5mg/ml poly-D-lysine
for 4–6h, followed by 5mg/ml EHS laminin for overnight. The
explants were kept in DMEM serum-free media containing 25mM
Hepes pH 7.4, 2mM L-glutamine, 5mg/ml bovine insulin, 100mg/ml
apotransferrin, 20nM progesterone, 100nM putrescine, 30nM
selenium, 100mM pyruvate 76mg/ml BSA and 50mg/ml gentamicin
(All from Invitrogen, Paisley, UK) and maintained at 371C, 5% CO2.
Consistent with previous ﬁndings (Bates and Meyer, 1997), 7475%
(percentage7s.e.m.) of retinal explants showed axonal outgrowth.
No signiﬁcant difference in axonal outgrowth efﬁciency was
detected between the cultures from human P301S tau transgenic
and C57/BL6 control mice (Gasparini et al, 2006). Immunohisto-
chemical analysis of tau and p150 was performed on retinal cultures
at 7 days in vitro. Cultures were ﬁxed with cold methanol for 5min,
blocked with 2% goat serum, 1% bovine serum albumin (BSA),
0.1% gelatin in TBS containing 0.1% Triton-X100 and incubated
overnight at 41C with primary antibodies diluted in 1% BSA, 0.1%
gelatin in PBS. For the anti-p150 antibody, the Alexa 488-tyramide
ampliﬁcation system was used (Invitrogen, Paisley, UK). For anti-
tau and anti-neuroﬁlament antibodies, Alexa 568-conjugated anti-
rabbit and Alexa-350-conjugated anti-mouse secondary antibodies
were used. Coverslips were mounted using Permaﬂuor (Lipshaw,
Pittsburgh, PA) mounting medium. Each reported immunohisto-
chemical staining was performed at least three times and four
coverslips were used for each staining.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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